Age (years) |
Age (years) |
|
|
0.429 |
Median |
48 |
47 |
48 |
|
IQR |
41-54 |
40-53 |
43-55 |
|
Family history of malignancy, n (%) |
Family history of
malignancy, n (%) |
|
|
0.737 |
None |
89 (86.4) |
53 (85.5) |
36 (87.8) |
|
Yes |
14 (13.6) |
9 (14.5) |
5 (12.2) |
|
Histology, n (%) |
Histology, n (%) |
|
|
0.858 |
Pure |
82 (79.6) |
49 (79.0) |
33 (80.5) |
|
Mixed |
21 (20.4) |
13 (21.0) |
8 (19.5) |
|
Tumor size, n (%) |
|
|
|
<0.001 |
<4cm |
62 (60.2) |
46 (74.2) |
16 (39.0) |
|
≥4cm |
41 (39.8) |
16 (25.8) |
25 (61.0) |
|
Lymph node |
|
|
|
<0.001 |
Negative |
71 (68.9) |
62 (100) |
9 (22.0) |
|
Positive |
32 (31.1) |
0 (0) |
32 (78.0) |
|
Chemotherapy regimen, n (%) |
Chemotherapy regimen, n
(%) |
|
|
0.341 |
EP |
66 (64.1) |
42 (67.7) |
24 (58.5) |
|
non-EP |
37 (35.9) |
20 (32.3) |
17 (41.5) |
|
Chemotherapy courses, n (%) |
Chemotherapy courses, n
(%) |
|
|
0.313 |
1-4 |
49 (47.6) |
32 (51.6) |
17
(41.5) |
|
≥5 |
54 (52.4) |
30 (48.4) |
24 (58.5) |
|
Chemotherapy sequencing, n (%) |
Chemotherapy sequencing,
n (%) |
|
|
0.358 |
IC |
4 (3.9) |
3 (4.8) |
1 (2.4) |
|
ACT |
62 (60.2) |
40 (64.5) |
22 (53.7) |
|
IC+ACT |
37 (35.9) |
19 (30.6) |
18 (43.9) |
|
Treatment modality, n (%) |
Treatment modality, n (%) |
|
|
0.004 |
S+CT |
39 (37.9) |
31 (50.0) |
8 (19.5) |
|
S+RT+CT |
52 (50.5) |
27 (43.5) |
25 (61.0) |
|
RT+CT |
12 (11.7) |
4 (6.5) |
8 (19.5) |
|